Summary
Serial assessment of ventricular function by means of radionuclide angiography was performed in 50 patients with malignant neoplasms who received either 4′-epidoxorubicin or mitoxantrone for longer than 3 months.
In 9 of 30 patients give 4′-epidoxorubicin, a decrease of ≥10% in the left ventricular ejection fraction (LVEF) was documented at doses of 143–1200 mg/m2. Two patients developed clinical signs of cardiotoxicity at a dose of >1000 mg/m2.
In 6 of 20 patients given mitoxantrone a decrease of ≥10% in the LVEF occurred at doses of 26–98 mg/m2.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Arcamone F, Penco S, Vigevani A, Redaelli S, Franchi G, Di Marco A, Casazza AM, Dasdia T, Formelli F, Necco A, Soranzo C (1975) Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone. J Med Chem 18: 703–707
Benjamin RS, Chawla SP, Ewer MS, Carrasco CH, Mackay B, Haynie (III) TP, Yap HY, Blumenschein GR, Holmes F, Ali MK, Bodey GP (1984) Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy. Proc Am Soc Clin Oncol 3: 40
Bishop J, Hillcoat B, Raghavan D, Jeal P, Coates A, Wood R, Snyder R (1984) Mitomycin C, mitoxantrone in previously treated patients with advanced breast cancer. Proc Am Soc Clin Oncol 3: 116
Bonfante V, Bonadonna G, Villani F, Di Fronzo G, Martini A, Gasazza AM (1979) Preliminary phase I study of 4′-Epi-Adriamycin. Cancer Treat Rep 63: 915–918
Bonfante V, Villani F, Bonadonna G (1982) Toxic and therapeutic activity of 4′-epi-doxorubicin. Tumori 68: 105–111
Casazza AM (1979) Experimental evaluation of anthracycline analogs. Cancer Treat Rep 63: 835–844
Casazza AM, DiMarco A, Bonadonna G, Bonfante V, Bertazzoli C, Bellini O, Pratesi G, Sala L, Ballerini L (1980) Effects of modifications in position 4 of the chromophore or in position 4′ of the aminosugar, on the antitumor activity and toxicity of daunorubicin and doxorubicin. In: Crooke ST, Reich SD (eds) Anthracyclines: current status and new developments. Academic, New York, pp 403–430
Crossley RJ (1983) Clinical safety and tolerance of mitoxantrone (Novantrone). Cancer Treat Rev 10 [suppl B]: 29–36
Dantchev D, Slioussartchok V, Paintrand M, Bourut D, Mathé G, Madeira-Coelho A (1980) Ultrastructural study of the cardiotoxicity and light microscopic findings of the skin after treatment of golden hamsters with seven different anthracyclines. Recent Results Cancer Res 74: 223–249
Falkson G, Vorobiof DA (1984) 4′-epidoxorubicin in colorectal cancer. In: Bonadonna G (ed), Advances in anthracycline chemotherapy: Epirubicin. Masson, Milano, pp 105–109
Foster B, Lev L, Bergmann C, Claggett-Carr C, Marsoni S (1984) Cardiac events in patients treated with mitoxantrone in phase II trials sponsored by the National Cancer Institute. Proc Am Assoc Cancer Res 25: 168
Gottdiener JS, Mathisen DJ, Borer JS, Bonon RO, Myers C, Barr LH, Schwartz DE, Bacharach SL, Green MV, Rosenberg SA (1981) Doxorubicin cardiotoxicity: Assessment of late ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 94: 430–435
Greenberg BH, Dren D, Botvinick EH, Werner JA, Klausner SC, Shames DM, Parmley WM (1980) Evaluation of left ventricular performance by gated radionuclide angiography. Clin Nucl Med 5: 245–254
Henderson BM, Dougherthy WJ, James VC, Tilley LP, Noble JF (1982) Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs compared with doxorubicin: I. Clinical observations. Cancer Treat Rep 66: 1139–1143
Henderson IC, Dukart G (1984) A randomized trial comparing mitoxantrone with doxorubicin in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 3: 120
Holmes F, Yap H, Buzdar A, Esparza L, Hortobagyi G, Blumenshein G, Ho DH, Bodey G (1984) Sequential chemotherapy with mitoxantrone, cyclophosphamide and fluorouracil followed by doxorubicin and vinblastine in advanced breast cancer. Proc Am Soc Clin Oncol 3: 124
Iturralde M, Van Aswegen A (1982) Radionuclide imaging and determination of ventricular function. In: Anghileri LJ (ed) General processes of radiotracer localization, vol 2, chap 2, CRC Press, Boca Raton
Jain JJ, Casper ES, Geller NL, Hakes TB, Kaufman RJ, Currie V, Schwartz W, Cassidy C, Petroni GR, Young CW, Wittes RE (1985) A prospective randomized comparison of doxorubicin and a less cardiotoxic analog, epirubicin, in patients with advanced breast cancer, submitted to Ann Intern Med
Kennedy JW, Sorensen SG, Ritchie JL, Folland ED, Hamilton GW (1978) Radionuclide angiography for the evaluation of anthracycline therapy. Cancer Treat Rep 62: 941–943
Lefrak EA, Pitha J, Rosenheim S, Gottlieb J (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32: 302–314
Maksymiuk AW, Bowman DM, Bodhurta AJ (1984) Mitoxantrone plus tamoxifen versus tamoxifen for metastatic breast cancer. Proc Am Soc Clin Oncol 3: 124
Murdock KC, Wallace RE, Durr FE, Child RG, Citarella RV, Fabio PF, Angier RB (1979) Antitumor agents: I. 1,4-Bis-(aminoalkylamino)-9, 10-anthracenediones. J Med Chem 22: 1024–1030
Okada RD, Pohost GM, Nicols AB, McKusik KA, Strauss HW, Boucher CA, Block PC, Rosenthal SV, Dinsmore RE (1980) Left ventricular regional wall motion assessment by multigated and end diastolic end systolic gated radionuclide left ventriculography. Am J Cardiol 45: 1211–1218
Posner LE, Dukart G, Goldberg J, Bernstein T, Cartwright K (1985) Mitoxantrone: An Overview of Safety and Toxicity. Investigational New Drugs 3: 123–132
Ritchie JL, Singer JW, Thorming D, Sorensen SG, Hamilton GW (1980) Anthracycline cardiotoxicity: Clinical and pathologic outcomes assessed by radionuclide ejection fraction. Cancer 46: 1109–1116
Rosso R, Nobile MT, Campora E, Conte PF, Chiara S, Muttini P, Fiorio P, Calciati A, Giaccone G, Clerico M, De Filippi PG, Picciotto G (1984) Comparative evaluation of cardiac toxicity of doxorubicin and 4′-epidoxorubicin, In: Bonadonna G (ed) advances in anthracycline chemotherapy: Epriubicin. Masson, Milano, p 19
Schauer PK, Wittes RE, Gralla RJ, Casper ES, Young CW (1981) A phase I trial of 4′-epi-adriamycin. Cancer Clin Trials 4: 433–437
Sparano BM, Gordon G, Hall C, Iatropoulos MJ, Noble JF (1982) Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: Comparison with doxorubicin: II. Histologic and ultrastructural pathology. Cancer Treat Rep 66: 1145–1158
Torti FM, Bristaw Bristaw MR, Howes AE, Aston D, Kohler M, Mitchell EP, Meyers FJ, Billingham ME (1984) Preliminary observations of epirubicin cardiac toxicity: methodologic considerations in the evaluation of doxorubicin and its analogs by endomyocardial biopsy, In: Bonadonna G (ed) advances in anthracycline chemotherapy: Epirubicin. Masson, Milano, p 20
Van Aswegen A, Herbst CP, Lötter MG, Otto AC, Kleynhans PHT, Minaar PC (1983) Variation in left ventricular ejection fraction determination at rest and during exercise. S Afr Med J 63: 890–892
Van Echo DA, Leone LA, Davis R, Santomauro B, Henderson E, Frei E (1984) A phase II study of mitoxantrone (NSC 301739) in patients with primary liver cancer. Proc Am Soc Clin Oncol 3: 143
Villani F, Favalli C, Piccinini F (1980) relationship between the effect on calcium turnover and early cardiotoxicity of doxorubicin and 4′-epidoxorubicin in guinea pig heart muscle. Tumori 66: 689–697
Villani F, Comazzi R, Guindani A, Crippa F (1984) Myocardial toxicity of 4′-epidoxorubicin: The experience of the National Cancer Institute of Milan. In: Bonadonna G (ed) advances in anthracycline chemotherapy: Epirubicin. Masson, Milano, p 17
Von Hoff DD, Layard MW, Basa P, Davis H, von Hoff A, Rozencweig M, Muggia F (1979) Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 91: 710–717
Vorobiof DA, Iturralde M, Falkson G (1983) Amsacrine cardiotoxicity: Assessment of ventricular function by radionuclide angiography. Cancer Treat Rep 67: 115–117
Vorobiof DA (1984) Radionuclide ventriculography for the assessment of left ventricular function in patients receiving cancer chemotherapy. Cancer Ther Update 4: 3
Wilson KS, Paterson AHG (1984) Single-agent mitoxantrone as first-line chemotherapy in advanced breast cancer. Proc Am Soc Clin Oncol 3: 117
Young CW, Casper ES, Geller NC (1984) Clinical and cineangiographic comparison of the cardiotoxic effects of epirubicin and doxorubicin, In: Bonadonna G (ed) advances in anthracycline chemotherapy: Epirubicin. Masson, Milano, p 18
Author information
Authors and Affiliations
Additional information
This study was supported in part by a grant from the National Cancer Association of South Africa
Rights and permissions
About this article
Cite this article
Vorobiof, D.A., Iturralde, M. & Falkson, G. Assessment of ventricular function by radionuclide angiography in patients receiving 4′-epidoxorubicin and mitoxantrone. Cancer Chemother. Pharmacol. 15, 253–257 (1985). https://doi.org/10.1007/BF00263896
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00263896